Transforming the Therapeutic Potential of ADCs with Next-Generation Cyanobacterial Toxin Payloads
- Simris Biologics is advancing a pipeline of best-in-class ADC payloads, derived from proprietary cyanobacterial technologies.
- Our unparalleled strain library is a rich source of novel payload candidates.
- Our lead Microcystin variant has demonstrated industry-competitive efficacy and a promising safety profile.
- We aim to create significant value through early-stage licensing deals with leading biopharma partners.
ANTIBODY DRUG CONJUGATES
Based upon our patent protected platform we are developing the next generation of safer ADC payloads with a high therapeutic index.
CYANOBACTERIAL TOXIN STANDARDS AND REAGENTS
Our range of high-quality standards and reagents are trusted by water authorities around the world.